Form 4: Achieve Life Sciences Executive Awarded Performance Restricted Stock Units

Jaime Xinos, Chief Commercial Officer of Achieve Life Sciences, was granted 100,000 performance-based restricted stock units (PRSUs) on January 28, 2025.

Summary

• Jaime Xinos, the Chief Commercial Officer of Achieve Life Sciences, was granted 100,000 Performance Restricted Stock Units (PRSUs) on January 28, 2025.
• Each PRSU represents a contingent right to receive one share of Achieve Life Sciences common stock upon settlement.
• The actual number of shares that will vest from the PRSUs can range from 0% to 100% of the initial grant, depending on the achievement of certain milestones during a specified measurement period.
• The PRSUs have an expiration date of January 28, 2035.

Sentiment

Score: 7

Explanation: The document reflects a standard executive compensation practice, which is generally positive as it aligns management with company performance. There are no negative implications.

Positives

• The grant of PRSUs aligns the executive's interests with the company's performance goals.
• The vesting of the PRSUs is contingent on achieving specific milestones, which can drive company performance.

Risks

• The actual number of shares that will vest is uncertain and depends on the achievement of performance milestones.
• If the performance milestones are not met, the executive may not receive the full 100,000 shares.

Future Outlook

The vesting of the PRSUs is contingent on the achievement of certain performance milestones during a measurement period, which will determine the final number of shares received.

Industry Context

The use of performance-based equity awards is a common practice in the biotechnology industry to incentivize executives and align their interests with shareholders.

Comparison to Industry Standards

• Performance-based equity awards are a standard practice in the biotech industry, with companies like Amgen, Gilead, and Biogen using similar structures to incentivize their executives.
• The vesting conditions tied to performance milestones are also common, ensuring that executives are rewarded for achieving specific company goals.
• The range of vesting from 0% to 100% is typical, reflecting the uncertainty and risk associated with biotech development.

Stakeholder Impact

• The grant of PRSUs aligns the executive's interests with those of shareholders, as the value of the award is tied to the company's performance.
• Employees may view this as a positive sign of the company's commitment to its leadership.

Key Dates

Keywords

Performance Restricted Stock Units, PRSU, Stock Options, Executive Compensation, Achieve Life Sciences, Jaime Xinos